Fulgent Genetics, Inc. filings document operating results, business updates, governance matters, capital-structure activity, and clinical disclosures for a company with laboratory services and therapeutic development operations. Form 8-K reports furnish earnings releases, investor presentation updates, stock repurchase activity, and material-event disclosures tied to the company's business and pipeline.
The company's proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and other governance disclosures. Clinical and regulatory filings include updates related to FID-007 in recurrent or metastatic head and neck squamous cell carcinoma, while broader disclosures address financial performance, risk, and capital allocation.
Fulgent Genetics, Inc. (FLGT) reported that its CFO and Treasurer, Paul Kim, had 2,087 shares of common stock withheld on September 1, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 25, 2025. After this tax-withholding disposition, Kim directly holds 356,543 shares of Fulgent Genetics common stock.
Fulgent Genetics, Inc. (FLGT) reported that Chief Executive Officer and director Ming Hsieh had 4,392 shares of common stock withheld on September 1, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 25, 2025. After this tax-withholding disposition, he directly holds 885,952 shares of common stock. He also reports indirect ownership through the Ming Hsieh Trust, the Dynasty Trust (for which he disclaims any beneficial interest except for any pecuniary interest), a Uniform Transfers to Minors Act account, and an immediate family member’s account, where he or related parties have varying voting and dispositive powers. No Rule 10b5-1 trading plan is reported for these transactions.
Fulgent Genetics, Inc. (FLGT) reported that Chief Scientific Officer Hanlin Gao sold 1,673 shares of common stock on September 2, 2026 at a weighted-average price of $19.66 per share. According to the disclosure, the sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units. Following this sale, Gao directly holds 986,117 shares of Fulgent Genetics common stock.
Fulgent Genetics, Inc. (FLGT) reports that President and COO Jian Xie sold 2,127 shares of common stock on September 2, 2026 at a weighted-average price of $19.6564 per share to satisfy tax withholding obligations arising from vesting of previously granted restricted stock units. Following this sale, he directly holds 359,924 shares and has indirect ownership of 220,816 shares held by The Hsieh Family Dynasty Trust, where he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest. No Rule 10b5-1 trading plan is reported for these transactions.
Fulgent Genetics, Inc. (FLGT) received a Rule 144 notice for proposed sales of its common stock for the account of officer Jian Xie. The securities relate to 45,304 shares of restricted stock that vested on February 25, 2025 as equity compensation for services.
The filing notes that this planned sale, together with recent transactions, is intended to satisfy tax withholding obligations through "sell to cover" arrangements and is not described as a discretionary trade by Jian Xie.
Fulgent Genetics, Inc. (FLGT) has a notice under Rule 144 for sales of common stock by officer Hanlin Gao. The notice covers a planned sale through Morgan Stanley Smith Barney LLC of 1,673 shares of common stock on September 2, 2026, when 27,515,293 shares were outstanding.
The shares relate to 37,790 restricted shares that vested on February 25, 2025 as equity compensation for services. Gao also reported sales of 1,688 shares on June 2, 2026 and 939 shares on August 27, 2026. All transactions are stated to be “sell to cover” for tax withholding, not discretionary trading.
Fulgent Genetics, Inc. (FLGT) reported an insider tax-withholding transaction by Chief Executive Officer and director Ming Hsieh. On 2026-08-26, 2,949 shares of common stock were withheld at $19.81 per share to satisfy tax obligations arising from the vesting of restricted stock units granted on February 26, 2024.
After this withholding, Hsieh directly held 890,344 common shares. He also has indirect holdings through The Ming Hsieh Trust, the Dynasty Trust (where he disclaims beneficial interest except for any pecuniary interest), a Uniform Transfers to Minor Act account for which he is custodian holding 1,000 shares, and 1,000 shares held by an immediate family member in the same household.
For Fulgent Genetics, Inc. (FLGT), CFO and Treasurer Paul Kim reported a Form 4 transaction involving 1,168 shares of common stock on 2026-08-26. The shares were withheld to satisfy tax withholding obligations triggered by the vesting of restricted stock units, not sold in an open-market trade. After this tax-withholding disposition, Kim’s directly held stake is 358,630 shares of common stock.
Fulgent Genetics, Inc. (FLGT) reported an insider transaction by President and COO Jian Xie. On 2026-08-27, Xie sold 1,193 shares of common stock at a weighted-average price of $19.9053 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 26, 2024. After this sale, Xie directly held 362,051 shares and had an additional 220,816 shares held indirectly through The Hsieh Family Dynasty Trust, for which he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics, Inc. (FLGT) reported that Chief Scientific Officer Hanlin Gao sold 939 shares of common stock on August 27, 2026, in an open-market transaction at a weighted-average price of $19.9053 per share, in multiple trades between $19.83 and $20.00. According to the disclosure, the sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 26, 2024. Following this sale, Gao directly holds 987,790 shares of Fulgent Genetics common stock.